Report cover image

Global Meningococcal Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 193 Pages
SKU # APRC20552071

Description

Summary

According to APO Research, The global Meningococcal Disease Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Meningococcal Disease Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Meningococcal Disease Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Meningococcal Disease Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Meningococcal Disease Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Meningococcal Disease Drugs include Yiling Pharmaceutical, SSY Group Limited, Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Lukang Pharmaceutical Co.,Ltd., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and North China Pharmaceutical Company Ltd., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Meningococcal Disease Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Meningococcal Disease Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Meningococcal Disease Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Meningococcal Disease Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Meningococcal Disease Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Meningococcal Disease Drugs sales, projected growth trends, production technology, application and end-user industry.

Meningococcal Disease Drugs Segment by Company

Yiling Pharmaceutical
SSY Group Limited
Apeloa Pharmaceutical Co.,Ltd.
Novartis
Merck Sharp & Dohme
Lukang Pharmaceutical Co.,Ltd.
Shandong Jincheng Pharmaceutical Group Co.,ltd.
Pfizer
North China Pharmaceutical Company Ltd.
Hebei Hejia Pharmaceutical Technology Group Co., Ltd
Harbin Pharmaceutical Group Co.,Ltd.
GlaxoSmithKline
Baiyunshan Pharmaceutical
Sanofi Pasteur
Meningococcal Disease Drugs Segment by Type

Injectable
Oral
Meningococcal Disease Drugs Segment by Application

Hospitals
Drugstores
Others
Meningococcal Disease Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Meningococcal Disease Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Meningococcal Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Meningococcal Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Meningococcal Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Meningococcal Disease Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Meningococcal Disease Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Meningococcal Disease Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Meningococcal Disease Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Meningococcal Disease Drugs Market Dynamics
2.1 Meningococcal Disease Drugs Industry Trends
2.2 Meningococcal Disease Drugs Industry Drivers
2.3 Meningococcal Disease Drugs Industry Opportunities and Challenges
2.4 Meningococcal Disease Drugs Industry Restraints
3 Meningococcal Disease Drugs Market by Manufacturers
3.1 Global Meningococcal Disease Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Meningococcal Disease Drugs Sales by Manufacturers (2020-2025)
3.3 Global Meningococcal Disease Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Meningococcal Disease Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Meningococcal Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Meningococcal Disease Drugs Manufacturers, Product Type & Application
3.7 Global Meningococcal Disease Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Meningococcal Disease Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Meningococcal Disease Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Meningococcal Disease Drugs Tier 1, Tier 2, and Tier 3
4 Meningococcal Disease Drugs Market by Type
4.1 Meningococcal Disease Drugs Type Introduction
4.1.1 Injectable
4.1.2 Oral
4.2 Global Meningococcal Disease Drugs Sales by Type
4.2.1 Global Meningococcal Disease Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Meningococcal Disease Drugs Sales by Type (2020-2031)
4.2.3 Global Meningococcal Disease Drugs Sales Market Share by Type (2020-2031)
4.3 Global Meningococcal Disease Drugs Revenue by Type
4.3.1 Global Meningococcal Disease Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Meningococcal Disease Drugs Revenue by Type (2020-2031)
4.3.3 Global Meningococcal Disease Drugs Revenue Market Share by Type (2020-2031)
5 Meningococcal Disease Drugs Market by Application
5.1 Meningococcal Disease Drugs Application Introduction
5.1.1 Hospitals
5.1.2 Drugstores
5.1.3 Others
5.2 Global Meningococcal Disease Drugs Sales by Application
5.2.1 Global Meningococcal Disease Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Meningococcal Disease Drugs Sales by Application (2020-2031)
5.2.3 Global Meningococcal Disease Drugs Sales Market Share by Application (2020-2031)
5.3 Global Meningococcal Disease Drugs Revenue by Application
5.3.1 Global Meningococcal Disease Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Meningococcal Disease Drugs Revenue by Application (2020-2031)
5.3.3 Global Meningococcal Disease Drugs Revenue Market Share by Application (2020-2031)
6 Global Meningococcal Disease Drugs Sales by Region
6.1 Global Meningococcal Disease Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Meningococcal Disease Drugs Sales by Region (2020-2031)
6.2.1 Global Meningococcal Disease Drugs Sales by Region (2020-2025)
6.2.2 Global Meningococcal Disease Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Meningococcal Disease Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Meningococcal Disease Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Meningococcal Disease Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Meningococcal Disease Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Meningococcal Disease Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Meningococcal Disease Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Meningococcal Disease Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Meningococcal Disease Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Meningococcal Disease Drugs Revenue by Region
7.1 Global Meningococcal Disease Drugs Revenue by Region
7.1.1 Global Meningococcal Disease Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Meningococcal Disease Drugs Revenue by Region (2020-2025)
7.1.3 Global Meningococcal Disease Drugs Revenue by Region (2026-2031)
7.1.4 Global Meningococcal Disease Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Meningococcal Disease Drugs Revenue (2020-2031)
7.2.2 North America Meningococcal Disease Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Meningococcal Disease Drugs Revenue (2020-2031)
7.3.2 Europe Meningococcal Disease Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Meningococcal Disease Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Meningococcal Disease Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Meningococcal Disease Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Meningococcal Disease Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Yiling Pharmaceutical
8.1.1 Yiling Pharmaceutical Comapny Information
8.1.2 Yiling Pharmaceutical Business Overview
8.1.3 Yiling Pharmaceutical Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Yiling Pharmaceutical Meningococcal Disease Drugs Product Portfolio
8.1.5 Yiling Pharmaceutical Recent Developments
8.2 SSY Group Limited
8.2.1 SSY Group Limited Comapny Information
8.2.2 SSY Group Limited Business Overview
8.2.3 SSY Group Limited Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 SSY Group Limited Meningococcal Disease Drugs Product Portfolio
8.2.5 SSY Group Limited Recent Developments
8.3 Apeloa Pharmaceutical Co.,Ltd.
8.3.1 Apeloa Pharmaceutical Co.,Ltd. Comapny Information
8.3.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
8.3.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
8.3.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
8.4 Novartis
8.4.1 Novartis Comapny Information
8.4.2 Novartis Business Overview
8.4.3 Novartis Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Novartis Meningococcal Disease Drugs Product Portfolio
8.4.5 Novartis Recent Developments
8.5 Merck Sharp & Dohme
8.5.1 Merck Sharp & Dohme Comapny Information
8.5.2 Merck Sharp & Dohme Business Overview
8.5.3 Merck Sharp & Dohme Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Merck Sharp & Dohme Meningococcal Disease Drugs Product Portfolio
8.5.5 Merck Sharp & Dohme Recent Developments
8.6 Lukang Pharmaceutical Co.,Ltd.
8.6.1 Lukang Pharmaceutical Co.,Ltd. Comapny Information
8.6.2 Lukang Pharmaceutical Co.,Ltd. Business Overview
8.6.3 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
8.6.5 Lukang Pharmaceutical Co.,Ltd. Recent Developments
8.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
8.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Comapny Information
8.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
8.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Product Portfolio
8.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
8.8 Pfizer
8.8.1 Pfizer Comapny Information
8.8.2 Pfizer Business Overview
8.8.3 Pfizer Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Pfizer Meningococcal Disease Drugs Product Portfolio
8.8.5 Pfizer Recent Developments
8.9 North China Pharmaceutical Company Ltd.
8.9.1 North China Pharmaceutical Company Ltd. Comapny Information
8.9.2 North China Pharmaceutical Company Ltd. Business Overview
8.9.3 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Product Portfolio
8.9.5 North China Pharmaceutical Company Ltd. Recent Developments
8.10 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
8.10.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Comapny Information
8.10.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
8.10.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Product Portfolio
8.10.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
8.11 Harbin Pharmaceutical Group Co.,Ltd.
8.11.1 Harbin Pharmaceutical Group Co.,Ltd. Comapny Information
8.11.2 Harbin Pharmaceutical Group Co.,Ltd. Business Overview
8.11.3 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
8.11.5 Harbin Pharmaceutical Group Co.,Ltd. Recent Developments
8.12 GlaxoSmithKline
8.12.1 GlaxoSmithKline Comapny Information
8.12.2 GlaxoSmithKline Business Overview
8.12.3 GlaxoSmithKline Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 GlaxoSmithKline Meningococcal Disease Drugs Product Portfolio
8.12.5 GlaxoSmithKline Recent Developments
8.13 Baiyunshan Pharmaceutical
8.13.1 Baiyunshan Pharmaceutical Comapny Information
8.13.2 Baiyunshan Pharmaceutical Business Overview
8.13.3 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Product Portfolio
8.13.5 Baiyunshan Pharmaceutical Recent Developments
8.14 Sanofi Pasteur
8.14.1 Sanofi Pasteur Comapny Information
8.14.2 Sanofi Pasteur Business Overview
8.14.3 Sanofi Pasteur Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Sanofi Pasteur Meningococcal Disease Drugs Product Portfolio
8.14.5 Sanofi Pasteur Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Meningococcal Disease Drugs Value Chain Analysis
9.1.1 Meningococcal Disease Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Meningococcal Disease Drugs Production Mode & Process
9.2 Meningococcal Disease Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Meningococcal Disease Drugs Distributors
9.2.3 Meningococcal Disease Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.